182 related articles for article (PubMed ID: 16042726)
1. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer.
Attallah AM; Sakr HA; Ismail H; Abdel-Hady el-SK; El-Dosoky I
BJU Int; 2005 Aug; 96(3):334-9. PubMed ID: 16042726
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
4. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Gupta NP; Sharma N; Kumar R
Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
[TBL] [Abstract][Full Text] [Related]
5. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
6. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
7. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
8. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations].
Fukui Y; Samma S; Fujimoto K; Akiyama T; Yamaguchi A; Hirayama A
Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750
[TBL] [Abstract][Full Text] [Related]
9. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
[TBL] [Abstract][Full Text] [Related]
10. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?].
Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM
Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217
[TBL] [Abstract][Full Text] [Related]
11. [The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22].
Chen HQ; Han CZ; Du LL; Cui Y; Pang DZ; Jing JX; Zhao XW; Tian BG; Mi ZG
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():84-6. PubMed ID: 17767866
[TBL] [Abstract][Full Text] [Related]
12. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
[TBL] [Abstract][Full Text] [Related]
13. Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer.
Takeuchi Y; Sawada Y; Yabuki D; Masuda E; Satou D; Kuroda K; Tajima M; Sawamura Y; Matsushima M
Aktuelle Urol; 2003 Jul; 34(4):265-6. PubMed ID: 14566681
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
15. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
16. [Significance and application of nuclear matrix protein 22 in detecting bladder cancer].
Liu GH; Li HZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):654-6. PubMed ID: 12901118
[TBL] [Abstract][Full Text] [Related]
17. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.
Schlake A; Crispen PL; Cap AP; Atkinson T; Davenport D; Preston DM
Can J Urol; 2012 Aug; 19(4):6345-50. PubMed ID: 22892257
[TBL] [Abstract][Full Text] [Related]
18. A dipstick, dot-ELISA assay for the rapid and early detection of bladder cancer.
Attallah AM; Helmi H; el-Helali E; el-Mohamadi H
Cancer Detect Prev; 1991; 15(6):495-9. PubMed ID: 1723657
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China.
Tsui KH; Chen SM; Wang TM; Juang HH; Chen CL; Sun GH; Chang PL
Asian J Androl; 2007 Sep; 9(5):711-5. PubMed ID: 17712491
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia.
Woodman AC; Goodison S; Drake M; Noble J; Tarin D
Clin Cancer Res; 2000 Jun; 6(6):2381-92. PubMed ID: 10873090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
